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Abstract 
 
Introduction: 
 
Despite the availability of consensus guidelines for treatment of vitamin D deficiency, there 
is a lack of prospective trials examining alternative dosing strategies for adult patients with 
cystic fibrosis (CF) who do not meet therapeutic goals with standard regimens. 
 
Objectives:  
 
The primary objective of this study was to determine the efficacy of high-dose 
cholecalciferol supplementation in increasing serum vitamin D (25-OHD) levels in adult 
patients with CF. 
 
Methods: 
 
Patients were eligible for inclusion if they were ≥18 years old, had baseline 25-OHD levels 
less than 30 ng/mL, and were diagnosed with CF and pancreatic insufficiency. Patients were 
given a single dose of cholecalciferol 300,000 or 500,000 IU based on baseline 25-OHD 
levels. Response was defined by 25-OHD and ionized calcium levels at 3 months. At 6 
months, responders received a second dose of the same strength, and non-responders were 
given a weekly supplement of cholecalciferol 50,000 IU in addition to cholecalciferol 
500,000 IU. A second 25-OHD level was obtained at 9 months.  
 
Results: 
 
Of 46 patients enrolled, 32 patients (70%) completed the study. Baseline levels of 25-OHD 
significantly increased over time in the per-protocol population at 3 months and 9 months.  
A total of 16 patients (50%) were considered non-responders and required weekly 
supplementation.  
 
Conclusion: 
 
A protocol using high-dose cholecalciferol or high-dose plus weekly cholecalciferol is safe 
and effective in treating adult patients with CF and pancreatic insufficiency. 
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Introduction 
 
Malabsorption of fat and fat-soluble vitamins A, D, E, and K due to pancreatic insufficiency is 
a common extra-pulmonary complication of cystic fibrosis (CF). In 2016, more than 80% of 
patients with CF under the age of 40 were taking pancreatic enzyme replacement therapy 
(PERT).1 Vitamin D deficiency an increasingly significant problem in this population because 
the median predicted survival age for patients with CF has improved to approximately 48 
years.1 Negative consequences of vitamin D deficiency include reduced peak bone mass, 
chronic bone pain, chest deformity, and increased risk of vertebral fractures.2 In addition, 
studies have demonstrated possible positive effects of adequate vitamin D levels on lung 
inflammation, pulmonary function, and CF-related diabetes.3-5  
Current standard of practice for vitamin D deficiency in patients with CF includes daily 
supplementation with cholecalciferol to maintain a goal serum 25-hydroxyvitamin D (25-
OHD) concentration of 30 ng/mL or greater.6-7 Because most patients with CF have 
pancreatic insufficiency and are not able to maintain this goal vitamin D level, large doses of 
supplemental vitamin D are required to overcome impaired absorption. The most recent 
consensus guidelines recommend a daily cholecalciferol dose of at least 800-2,000 IU. This 
may be accomplished with a CF multivitamin with high content of vitamins A, D, E, and K; 
however, patients often require additional cholecalciferol supplementation, further 
increasing pill burden. For patients who are still not within goal, recommendations are to 
increase the dose to as much as 10,000 IUs per day.6 There is a lack of prospective trials 
examining alternative dosing strategies in adult patients with CF who do not meet goals of 
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therapy on standard regimens. 
The efficacy of single, high-dose cholecalciferol (ie, stoss dosing) was evaluated in 38 
children with CF.8 Patients received a single oral dose of cholecalciferol 100,000 – 600,000 
IUs followed by a recommended intake of 800 IUs vitamin D as maintenance therapy. Dosing 
was individualized based on 25-OHD and age. Patients older than 12 years received doses of 
300,000 IU, 500,000 IU, or 600,000 IU based on 25-OHD levels of 20-30 ng/mL, 10-20 ng/mL 
and ≤10 ng/mL, respectively. Mean 25-OHD levels recorded at 1, 3, and 6 months were 
above the goal level of 30 ng/mL; however, at the 12-month time point, mean 25-OHD fell 
below goal to 25.9 ng/mL. No adverse effects of therapy were reported. The findings of this 
study showed safety and partial efficacy of stoss dosing in children with CF.8  
The efficacy of stoss dosing in pediatric patients with CF is promising. However, stoss dosing 
has not been studied in adults with CF. The objective of the current study was to determine 
if two treatments with high-dose cholecalciferol would allow adult patients with CF to reach 
and maintain goal 25-OHD levels. 
 
Methods 
 
Study Design 
 
This study was an open-label, prospective study, with patients serving as their own controls. 
The study design was reviewed and approved by the Indiana University-Purdue University 
Indianapolis (IUPUI) institutional review board (IRB), and the study began enrolling patients 
in October 2015. Patients received cholecalciferol doses based on baseline serum 25-OHD 
levels of 25-OHD 20-<30 ng/mL (300,000 IUs) or 25-OHD <20 ng/mL (500,000) (Figure 1). 
Dosing was based on the pediatric stoss dosing study8, but simplified to include the two 
lower dosing options due to low anticipation of patients with 25-OHD ≤10 ng/mL. Patients 
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were not prescribed additional daily vitamin D supplementation, but they were instructed to 
continue taking their CF multivitamin. At 3 months, the 25-OHD concentration was 
repeated. If serum 25-OHD was less than 45 ng/mL, patients were eligible to receive a 
second dose of cholecalciferol at 6 months. The upper limit of 45 ng/mL was chosen 
because of the potential for toxicity with redosing when 25-OHD levels exceed 45 ng/mL, 
the upper limit of normal at our institution. The 25-OHD level was measured again after 9 
months.  
Calcium levels were also obtained as a safety endpoint at 3 months following original dose. 
Patients with calcium above normal laboratory limits (calcium >10.5 mg/dL or ionized 
calcium >5.4 mg/dL) would be ineligible to receive the dose of cholecalciferol at 6 months.  
 
Patient Selection 
 
Established patients of the Indiana University (IU) Health Adult Cystic Fibrosis Clinic were 
eligible for inclusion in this study if they were at least 18 years of age, diagnosed with CF and 
pancreatic insufficiency, and had a recorded baseline 25-OHD of <30 ng/mL in the last 5 
months. Patients who were pregnant or who had undergone lung transplantation were 
excluded. A retrospective chart review was conducted to identify patients who had 25-OHD 
levels <30 ng/mL at each quarterly clinic visit or inpatient admission to the pulmonary 
service at IU Health University Hospital. Target enrollment was 40 patients based on power 
calculation assuming a 40% change from baseline based on the published stoss study 
results.8 Baseline characteristics collected included age, gender, genotype (presence of 
F508del or G551 mutation), weight, height, body mass index (BMI), use of a CF 
transmembrane conductance regulator (CFTR) modulator, hospitalization status at 
enrollment, and baseline forced expiratory volume at 1 second (FEV1) percent predicted.  
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Patients were excluded from analysis if they withdrew from the study, entered hospice 
treatment, or received lung transplantation during the study period. Additionally, patients 
were considered lost to follow up and excluded from the analysis if a 25-OHD level was >90 
days overdue.  
 
Description of Study Treatments 
 
Cholecalciferol was supplied as a 50,000 IU capsule, with dose of either 6 or 10 capsules 
depending on baseline 25-OHD. Patients were given a high-fat snack or dietary supplement 
and water to take with their dose. Patients were encouraged, but not required, to take PERT 
with the dose. Study personnel directly observed administration of each cholecalciferol 
dose.  
 
Protocol Change 
 
At interim analysis, the investigators identified a large variation in response to treatment. 
After reviewing the initial results, an interdisciplinary group made up of the clinic physician, 
nurse practitioner, dietician, and clinical pharmacists determined that a protocol change 
was needed. Two distinct treatment arms were formed: responders and non-responders. 
Responders were defined as patients with a ≥25% increase from baseline in 25-OHD or who 
met goal of ≥30 ng/mL. Treatment continued as planned at 6 months for responders. In 
non-responders, who were defined as patients with any decrease, increase of <25%, or a 3-
month 25-OHD <20 ng/mL, a weekly dose of cholecalciferol 50,000 units was initiated 
immediately following determination of non-response (see Figure 2). While some 
participants had 25-OHD levels that were suboptimal (<30 ng/mL), the investigators chose 
not to initiate additional supplemental 25-OHD in patients who meet criteria as a responder 
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due to concerns for hypervitaminosis D, lack of prior experience with stoss dosing at 6-
month intervals, and the large percent increases seen in some patients. The new protocol 
was reviewed and approved by the IRB in April 2016. All patients were re-consented and 
treated as directed by the updated protocol. 
 
Statistical Analysis 
 
The primary endpoint was change in 25-OHD over time per the updated protocol. Repeated 
measures ANOVA with Bonferroni correction was used to determine change in 25-OHD over 
time. Subgroup analysis for change in 25-OHD over time in responders and non-responders 
was not performed because of the small sample sizes for each group. Post-hoc logistic 
regression analysis identified factors associated with response, including age, gender, 
weight, BMI (and BMI <18 kg/m2), FEV1 at baseline, CFTR modulator status, presence of 
F508del or G551 mutations, and hospitalization status at dose 1. Additionally, Fisher’s exact 
test was used to test whether enrollment in spring/summer versus fall/winter impacted 
response or if there was seasonal variation in goal attainment at month 9. Statistical 
significance was defined as a p-value of <0.05 for all endpoints (SPSS v24, IBM, Armonk, NY). 
 
Results 
Of the 46 patients who were enrolled, 32 patients (70%) completed the study per protocol. 
Patients who completed the study were evenly distributed between male/female, were on 
average 25.7 years with FEV1 of 53%, and 94% had at least one copy of F508del  (Table 1). 
Seven patients were taking CFTR modulators on enrollment, including ivacaftor (n=4) and 
ivacaftor/lumacaftor (n=3). Three patients initiated ivacaftor/lumacaftor within 1 month of 
the initial dose, and one patient who was taking ivacaftor before enrollment discontinued 
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the medication after the initial cholecalciferol dose. There were 14 patients excluded from 
analysis, with the majority being lost to follow up (n = 10). Other reasons for exclusion, in 
one patient each, were lung transplantation, hospice admission, physician withdrawal due 
to concern for severe intestinal malabsorption with history of multiple bowel resections for 
distal intestinal obstruction syndrome, and patient withdrawal of consent.  
For patients completing the study protocol, 25-OHD levels significantly increased over time 
(Figure 3). The difference remained significant between baseline and months 3  and 9, 
respectively. By the end of the study, mean 25-OHD levels increased by 13.78 ng/mL over 
mean baseline levels. A total of 16 patients were considered non-responders and required 
additional weekly supplementation. No significant differences in baseline characteristics 
existed between responders vs non-responders (Table 2), with numerical differences noted 
in age (27 vs 24 years), gender distribution (44% vs 56% male), and hospitalization on 
enrollment (50% vs 38% hospitalized).All patients, including the non-responders, achieved 
levels above 20 ng/mL by month 9. At the end of the study, 18 patients (56%) had 25-OHD 
at goal of 30 ng/mL or above, with 9 patients from both the responder and non-responder 
groups reaching this target. 
 Season of enrollment did not affect response, with 40% of patients with baseline levels in 
spring/summer (n = 4 of 10) vs 55% in fall/winter (n = 12 of 22) classified as responders 
(p=0.7). Goal attainment was not significantly different in patients with 25-OHD levels 
drawn in spring/summer compared to the fall/winter seasons, with 55% and 43% of patients 
classified as responders with 3-month levels drawn in spring/summer (n=10 of 18) and 
fall/winter (n= 6 of 14), respectively (p=0.72). All calcium levels obtained were within or 
below normal limits, with mean serum calcium of 8.81 mg/dL and ionized calcium of 4.6 
mg/dL. No adverse effects were reported during the study period. Logistic regression did 
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not identify factors that predicted response to treatment, including genotype or CFTR 
modulator status. All variables tested, including age, gender, weight, BMI, BMI <18 kg/m2, 
FEV1 at baseline, CFTR modulator status, presence of F508del or G551 mutations, and 
hospitalization at dose 1 were not significant (p>0.05). Of note, all 4 patients taking ivacaftor 
did respond to treatment, while only 1 of the 3 patients taking ivacaftor/lumacaftor at 
baseline responded to treatment. Though these differences were not statistically significant, 
trials with larger number of patients may find increased response in those with residual 
function gating mutations on ivacaftor. After the initial cholecalciferol dose was given, 3 
additional patients initiated ivacaftor/lumacaftor, all within one month of the initial dose. 
Two of these patients were non-responders at 3 months and one failed to meet criteria for 
response even at month 9, suggesting that Vitamin D deficiency may persist despite 
treatment with CFTR modulators. The percent of patients taking CFTR modulators who met 
goal at month 9 was 56%, which mirrors the larger study population. Other variables 
considered but found to have no difference included age, FEV1 percent predicted, 
hospitalization status, BMI <18 kg/m2, and gender.  
 
Discussion  
This study demonstrated that a protocol of high-dose cholecalciferol or high-dose plus 
weekly cholecalciferol safely and effectively increases 25-OHD concentration to therapeutic 
levels. A majority of patients in the study were able to achieve goal 25-OHD levels of ≥30 
ng/mL, with equal rates between the responders and non-responders at month 9. 
Responders did not require daily supplementation outside of their CF multivitamin and 
could benefit from both reduced pill burden and increased compliance, as the high-dose 
cholecalciferol therapy can be administered in the clinic or inpatient setting at a very low 
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cost. In a study estimating treatment burden on adult patients with CF, patients reported 
taking a median of 3 unique oral medications in addition to pancreatic enzymes, with a 
range of 0-7, and dosing often required multiple times a day.9 Non-responders required an 
additional weekly 50,000 IU dose of cholecalciferol. It is possible that more frequent stoss 
doses could be used to obtain goal 25-OHD in these patients, but this strategy has not been 
studied to date.  
Approximately 40% of adults with CF have severe lung disease and meet clinical criteria for 
osteoporosis. The need for adequate vitamin D dosing is evident.10 The results of the 
present study are encouraging because earlier studies have demonstrated lack of response 
to alternative treatment regimens. One study examining Vitamin D supplementation in 
adults with CF found that <10% of patients treated with 50,000 IU cholecalciferol weekly for 
8 weeks reached a 25-OHD of ≥30 ng/mL,11 and the mean increase was only 0.3 ng/mL over 
baseline levels.10 While the pediatric stoss dosing study demonstrated significant increases 
in 25-OHD at all time points, the mean 25-OHD levels achieved were below goal at month 
12.8 Given this finding, the study evaluated endpoints at 3 and 9 months to allow for dosing 
every 6 months with follow up levels at the standard of care schedule of quarterly clinic 
visits. 
In this study, 50% were considered non-responders. This rate is much higher than other 
previously reported studies.8,12 Though neither weight nor BMI predicted response in our 
post-hoc analysis, it is possible that the differing body composition of adults as compared to 
children could explain some differences in response. Genotype and CFTR modulator status 
also did not predict response. This study was not powered to detect differences in these 
variables, and larger studies may be needed to identify predictors.  
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The present study was conducted in Indianapolis, Indiana, United States, which has on 
average only 186 days of sunshine annually.13 Though no direct comparison data are 
available, the potential for decreased exposure to sunlight when compared to other studied 
populations could impact absorption of vitamin D from the skin. Seasonal variations in 25-
OHD level are known to occur, and patients were enrolled throughout the year to minimize 
potential bias; however, individual variations in sun exposure could confound results.  
There are limitations to the present study, including the unblinded design and single 
treatment center. The 30% attrition rate was largely due to patients being lost to follow up, 
defined as failure to return to clinic within 90 days. Compliance with weekly doses of 
cholecalciferol was not tracked. The protocol was used in a real-world setting, with many of 
the doses and levels obtained after desired time frame. Though overdue levels and doses 
may lead to lower 25-OHD levels, this aids in validity for a clinic setting in which patients 
frequently reschedule appointments or get off schedule for their quarterly visits due to 
hospitalization or illness. Additionally, there was a need for a protocol revision midway 
through the study. Though all patients were re-consented on the updated protocol, the 
study was not originally designed or powered for the dual-pathway approach. As patients 
frequently changed brand of CF multivitamin due to cost and availability, the amount of 
background therapy may have varied slightly during the study period (between 2,000 and 
3,000 IU). We elected not to collect CF multivitamin brand(s) used during the study period 
for simplicity, but some changes in supplement may have impacted 25-OHD level. However, 
given that all patients were prescribed a CF multivitamin prior to study initiation, the impact 
of these variations are likely minimal.  
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While these limitations exist, the present study has encouraging results. Despite the large 
portion of patients with very low baseline 25-OHD levels, a level of ≥20 ng/mL was obtained 
for all participants. While wewere initially concerned about elevated 25-OHD levels, there 
were no levels at or above the laboratory standard upper limit of normal of 50 ng/mL. 
Calcium levels were also either below or within normal limits, and no adverse effects of 
therapy were reported. With the safety of this regimen established, future studies could be 
conducted to determine if more frequent stoss doses could be used in non-responders to 
maintain goal 25-OHD. Additionally, use in conjunction with new formulations of CF 
multivitamins with higher cholecalciferol content (up to 5,000 IU/dose) could help reduce 
need for further supplementation in some patients. 
 
Conclusion 
A protocol using high-dose cholecalciferol or high-dose plus weekly cholecalciferol is safe 
and effective in increasing 25-OHD levels in adult patients with CF and pancreatic 
insufficiency. This dosing strategy could help reduce pill burden for patients who respond to 
treatment, avoiding the need for daily supplementation with additional cholecalciferol.  
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Table 1. Baseline Characteristics 
 
Characteristic (n=32) 
Mean  Standard 
Deviation 
Age (years) 25.7  6.5 
Male (n, %) 16 (50) 
Genotype (n, %) 
F508del present 
  Heterozygous 
  Homozygous 
G551 present 
 
30 (94%) 
13 (41%) 
17 (53%) 
3 (9%) 
Weight (kg) 57.8  12.7 
BMI (kg/m2) 21.3  3.7 
BMI <18 (n, %) 7 (22) 
FEV1 Baseline (% predicted) 53  19 
CFTR modulator on enrollment (n, 
%) 
7 (22) 
Hospitalized on enrollment (n, %) 14 (44) 
Baseline 25-OHD (ng/mL) 18.8  6.1 
BMI = body mass index; FEV1 = forced expiratory volume at 1 second; CFTR = cystic fibrosis transmembrane 
conductance regulator; 25-OHD = 25-hydroxyvitamin D 
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Table 2. Characteristics of Responders vs Non-responders 
 
Characteristic  Responders  (n=16) Non-Responders (n=16) 
Age (years) 27.2  7.8 24.1  4.7 
Male (n, %) 7 (44%) 9 (56%) 
Genotype (n, %) 
F508del present 
  Heterozygous 
  Homozygous 
G551 present 
 
15 (94%) 
8 (50%) 
6 (38%) 
3 (19%) 
 
15 (94%) 
4 (25%) 
11 (69%) 
0  
Weight (kg) 58.9  14.5 56.7  11 
BMI (kg/m2) 21.5  3.8 21  3.7 
BMI <18 (n, %) 3 (19%) 4 (25%) 
FEV1 Baseline (% predicted) 52  21 54  17 
CFTR modulator on enrollment (n, 
%) 
4 (25%) 
3 (19%) 
Hospitalized on enrollment (n, %) 8 (50%) 6 (38%) 
Baseline 25-OHD (ng/mL) 18.6  6 19  6.4 
BMI = body mass index; FEV1 = forced expiratory volume at 1 second; CFTR = cystic fibrosis transmembrane 
conductance regulator; 25-OHD = 25-hydroxyvitamin D 
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Figure 3. Mean increase in 25-OHD over time 
 
 
Overall, p<0.001; Baseline to Month 3, p=0.011; Baseline to Month 9, p<0.001; Month 3 to 9, p>0.05 
Error bars represent standard deviation of overall mean; Goal 25-OHD as defined by CF Foundation 
recommendations6 
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